CD14 and melanoma: A high monocyte frequency is however not always associated with a poorer response, as demonstrated by Krieg et al. who found a higher frequency of classical monocytes (CD14+CD16−CD33hiHLA-DRhi), measured before therapy by single-cell mass cytometry, in melanoma patients responding to anti-PD-1.